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1. Introduction  
Recurrent pregnancy loss (RPL) is usually defined as the loss of three or more consecutive 
pregnancies before 20 weeks of gestation. Within this definition is a large and heterogeneous 
group of patients with many different causes of miscarriage. RPL is a common clinical 
problem that occurs in approximately 1 % of reproductive-aged women. However, this 
frequency increases up to 5% when clinicians define RPL as two or more losses of 
pregnancy. In addition, epidemiological investigations have demonstrated that the 
frequency of subsequent pregnancy loss is 24% after two pregnancy losses, 30% after three 
and 40% after four successive pregnancy losses. In many cases, the etiology is unknown, but 
several hypotheses have been proposed, including chromosomal and uterine anatomic 
abnormalities, endometrial infections, endocrine abnormalities, antiphospholipid syndrome, 
inherited thrombophilias, alloimmune causes, genetic factors, exposure to environmental 
factors and unexplained causes. Recently, it has become clear that prothrombotic changes 
are associated with a substantial proportion of these fetal losses. Therefore, the role of 
thrombophilias in RPL has generated a great deal of interest. This heterogeneous group of 
disorders results in increased venous and arterial thrombosis. Although some thrombophilic 
states in RPL may be acquired such as antiphospholipid antibody syndrome (APAS), most 
are heritable such as hyperhomocyteinemia, activated protein C resistance, deficiencies in 
proteins C and S, mutations in prothrombin, and mutations in antithrombin III. 
Data suggest that women with thrombophilia have an increased risk of pregnancy loss and 
other serious obstetric complications, including placental abruption, pre-eclampsia, 
intrauterine growth restriction and intrauterine fetal death. Recent attention has focused on 
thrombophilic factors that might be associated with pregnancy complications, including 
early pregnancy loss. Additionally pregnancy complications including idiopathic fetal loss 
are thought to result from placental under perfusion due to occlusive events, including 
thrombosis of placental vessels. Thrombosis of placental vessels is multicausal in nature and 
may involve both acquired and inherited risk factors, leading to RPL. It has been reported 
that genetic tendencies to thrombosis may also be associated with recurrent pregnancy loss. 
The three most common genetic markers for thrombophilia which are known to predispose 
to venous thrombosis are; factor V Leiden (FVL), methylenetetrahydrofolate reductase 
mutation (MTHFR, C677T) and prothrombin gene mutation (FII, G20210). In this chapter, 
we discuss the association of thrombophilia and RPL; these include important roles in 
management and treatment that appear to be required for normal pregnancy.  
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2. Recurrent pregnancy loss 
Recurrent pregnancy loss (RPL) is usually defined as the loss of three or more consecutive 
pregnancies before 20 weeks of gestation or with fetal weights less than 500 grams. Within 
this definition is a large and heterogeneous group of patients with many different causes of 
miscarriage. RPL affects approximately 1 % of couples (1). However, this frequency 
increases up to 5% when clinicians define RPL as two or more losses of pregnancy (2) In 
addition, epidemiological investigations have demonstrated that the frequency of 
subsequent pregnancy loss is 24% after two pregnancy losses, 30% after three and 40% after 
four successive pregnancy losses (3). Additionally, recurrent risk for RPL may increase up to 
50 percent even after six losses (4). Remarkably, the maternal and paternal age may 
approach the risk of pregnancy loss (Table 1) (5). Maternal age at conception and previous 
reproductive history are strong and independent risk factors for RPL. The chance of 
successful pregnancy in a woman aged 40 years or more and a man aged 40 years or more is 
poor. In many cases, the etiology is unknown, but several hypotheses have been proposed, 
including chromosomal and uterine anatomic abnormalities, endometrial infections, 
endocrine abnormalities, antiphospholipid syndrome, inherited thrombophilias, 
alloimmune causes, genetic factors, exposure to environmental factors and unexplained 
causes (Table 2) (6). The normal coagulation pathway is pivotal for the pregnancy outcomes 
(Table 3). Also any kind of disorder in coagulation pathway may cause thrombophilia that 
may be the reason of plasental insufficiency and PL (7). Recently, it has become clear that 
prothrombotic changes are associated with a substantial proportion of these fetal losses. 
Therefore, the role of thrombophilias in RPL has generated a great deal of interest. This 
heterogeneous group of disorders results in increased venous and arterial thrombosis. 
Although some thrombophilic states in RPL may be acquired such as antiphospholipid 
antibody syndrome (APAS), most are heritable such as hyperhomocyteinemia, activated 
protein C resistance, deficiencies in proteins C and S, mutations in prothrombin, and 
mutations in antithrombin III. 
 
Maternal Age Rate of PL (%) Paternal Age Rate of RPL (%) 
< 20 12.2 < 20 12 
20-24 14.3 20-24 11.8 
25-29 13.7 25-29 15.7 
30-34 15.5 30-34 13.1 
35-39 18.7 35-39 15.8 
40-44 25.5 40-44 19.5 
 
Table 1. The relationship between the spontaneous pregnancy loss and the maternal and 
paternal age. 
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Etiology Proposed Incidence 
(%) 
Genetic Factors 3.5-5 
Chromosomal, Single gene defects, Multifactorial  
Anatomic Factors 12-16 
Congenital  -Incomplete mullerian fusion or septum resorption 
                      -Diethylstilbestrol exposure 
                      -Uterine artey anomalies  
                      -Cervical incompetence 
Acquired      -Cervical incompetence 
                      -Synechiae 
                      -Leiyomyomas 
                      -Adenomyomas 
 
Endocrine Factors 17-20 
Luteal phase insufficiency, Polycystic ovarian syndrome, Diabetes 
mellitus, Thyroid disorders, Prolactin disorders 
 
Infectious Factors 0.5-5 
Bacteria, Viruses, Parasites, Zoonotic, Fungal  
Immunologic and Trombotic Factors 20-50 
Cellular mechanisms, Humoral mechanisms , Antiphospholipid 
Antibody Syndrome,  
Inherited Thrombophilias such as activated protein C resistance 
associated with mutations in factor V Leiden, deficiencies in protein 
C and S, mutations in the gene encoding methylene tetrahydrofolate 
reductase, mutations in the promoter region of the prothrombin, 
hyperhomocyteinemia,    
 
Table 2. Proposed Etiologies for Recurrent Spontaneous Abortion. 
2.1 Antiphospholipid antibody syndrome 
Pregnancy-specific antigens can elicit humoral responses, and patients with RPL can display 
altered humoral responses to endometrial and trophoblast antigens (8, 9). Nevertheless, 
most literature surrounding humoral immune responses and RPL focus on organ-
nonspecific autoantibodies associated with APAS. Historically, these IgG and IgM 
antibodies were thought to be directed against negatively charged phospholipids. Those 
phospholipids most often implicated in RPL are cardiolipin and phosphatidylserine. Most 
recently, however, it has been shown that antiphospholipid antibodies often are directed 
against a protein cofactor, called β2 glycoprotein 1, that assists antibody association with the 
phospholipid (10). The association of these antiphospholipid antibodies with thrombotic 
complications has been termed the antiphospholipid syndrome, and although many of these  
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aPC: activated protein C 
AT: Antithrombin 
PC: Protein C 
PS: Protein S 
TAFI: Trombin activated fibrinolyse inhibitor 
TM: Thrombomodulin 
Table 3. Coagulation pathway and factors 
complications are systemic, some are pregnancy specific—spontaneous abortion, stillbirth, 
intrauterine growth retardation, and preeclampsia (11). 
Diagnosis of this syndrome requires at least one of each clinical and laboratory criterion (12). 
These are listed below.  
Clinical 
 One or more confirmed episode of vascular thrombosis of any type 
- Venous 
- Arterial 
- Small vessel 
 Pregnancy complications 
- Three or more consecutive spontaneous pregnancy losses at less than 10 weeks of 
gestation 
- One or more fetal deaths at greater than 10 weeks of gestation 
- One or more preterm births at less than 34 weeks of gestation secondary to severe 
preeclampsia or placental insufficiency 
Laboratory 
(Testing must be positive on two or more occasions, 6 weeks or more apart.) 
 Positive plasma levels of anticardiolipin antibodies of the IgG or IgM isotype at 
medium to high levels 
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 Positive plasma levels of lupus anticoagulant 
The presence of antiphospholipid antibodies (anticardiolipin or lupus anticoagulant) during 
pregnancy is a major risk factor for an adverse pregnancy outcome (13). In large series of 
couples with recurrent abortion, the incidence of the APAS was between 3% and 5% (14). 
The presence of anticardiolipin antibodies among patients with known systemic lupus 
erythematosus portends less favorable pregnancy outcome (15). 
A number of mechanisms whereby antiphospholipid antibodies might mediate pregnancy loss 
have been proposed. Antibodies against phospholipids have been proposed to cause fetal loss 
because these antibodies inhibit release of prostacyclin, a potent vasodilator and inhibitor of 
platelet aggregation. In contrast, platelets produce thromboxane A2 which is a vasoconstrictor 
that also promotes platelet aggregation. These autoantibodies have also been shown to inhibit 
protein C activation, which results in coagulation and fibrin C formation. Clinically, these 
events might lead to hypercoagulability and recurrent thrombosis within the placenta. Women 
with both a history of early fetal loss and high levels of these antibodies may have a 70 percent 
miscarriage recurrence (16). In a prospective study of 860 women screened for anticardiolipin 
antibody in the first trimester reported that 7 percent tested positive (17). Miscarriage 
developed in 25 percent of the antibody-positive group, compared with only 10 percent of the 
negative group. In another study, there was no association between early pregnancy loss and 
the presence of either anticardiolipin antibody or lupus anticoagulant (18). 
2.2 Inherited thrombophilias 
Thrombophilic disorders have generated considerable interest in the field of RPL. 
Thrombophilia is an important predisposition to thrombosis due to a procoagulant state. 
Several blood clotting disorders are grouped under the term of thrombophilia. In table 4, 
thrombophilic mutations were described. Amongst these, are activated protein C 
resistance (APCR), protein S deficiency, protein C deficiency, prothrombin mutation, 
antithrombin III deficiency and hyperhomocysteinaemia (methylenetetrahydrofolate 
reductase mutation, C677 T MTHFR). Clinical studies suggest that the underlying 
pathophysiological mechanism is mediated via hypercoagulation, leading to uteroplacental 
insufficiency with resultant pregnancy loss. The basis for the association between adverse 
fetal outcomes and heritable thrombophilias has focused on the mechanisms of impaired 
placental development and function secondary to venous or arterial thrombosis at the 
maternal–fetal interface. Activation of protein S synergizes with activated protein C, thereby 
inhibiting the actions of clotting factors V and VIII. Thus, proteins S and C have an 
anticoagulant effect. Decreased action of these proteins has been postulated to increase the 
risk for pregnancy loss. Mutation in the gene encoding factor V results in a protein that is 
resistant to the effects of activated protein C (aPC). The most common of a variety of 
mutations is at position 506 with a glutamine substitution for arginine, this FV:R506Q 
mutation is called the factor V Leiden mutation (19, 20, 21). The mutation results in a protein 
resistant to the effects of aPC. The net result is increased the cleavage of prothrombin to 
thrombin, which causes excessive coagulability. Inherited decreased or absent antithrombin 
III activity will lead to increased thrombin formation and clotting. Prothrombin gene 
mutation is signalled by a defect in clotting factor II at position G20210A. The relative risk 
for thrombosis in patients with this mutation is two-fold in heterozygotes. Individuals with 
hyperhomocysteinaemia exhibit a deficiency of folate due to the presence of the methylene 
tetrahydrofolate reductase mutation (MTHFR C677 T). The thrombotic risk is increased two-
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fold in homozygosity; and in the heterozygous state for Antithrombin III deficiency, the risk 
is 20- to 50-fold. APCR has emerged as the commonest genetic cause of thrombo-embolism. 
APCR is caused by a point mutation (Factor V Leiden, FVL) in 95% of cases.  The risk of 
thrombosis is increased 5- to 10-fold in heterozygous carriers of FVL, and 100-fold in 
homozygosity (22, 23) Consistent with general thrombotic risk, carriage of combinations of 
two or more inherited thrombophilic defects has particularly strong association with 
adverse pregnancy outcomes (24, 25, 26). Considerable attention has been directed recently 
toward a possible relationship between thrombophilias and certain pregnancy 
complications other than venous thrombosis (27). Table 5 summarizes the findings of 79 
studies systematically reviewed by Robertson and associates (28). 
 
 
 
 
 
 
 
 
 
Table 4. Effects of inherited thrombophilia on the coagulation pathway. 
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Thrombophilia Early 
Pregnancy 
Loss 
Stillbirth Preeclampsia Placental 
Abruption 
Fetal-
Growth 
Restriction 
FVL—homozygous 2.7  
(1.3–5.6) 
2.0  
(0.4–9.7)
1.9 (0.4–7.9) 8.4  
(0.4–171.2) 
4.6  
(0.2–115.7) 
FVL—heterozygous 1.7  
(1.1–2.6) 
2.1  
(1.1–3.9)
2.2 (1.5–3.3) 4.7  
(1.1–19.6)
2.7  
(0.6–12.1) 
Prothrombin—
heterozygous 
2.5  
(1.2–5.0) 
2.7  
(1.3–5.5)
2.5 (1.5–4.2) 7.7  
(3.0–19.8)
2.9  
(0.6–13.7) 
MTHFR—homozygous 1.4  
(0.8–2.6) 
1.3  
(0.9–1.1)
1.4 (1.1–1.8) 1.5  
(0.4–5.4) 
1.2  
(0.8–1.8) 
Hyperhomocysteinemia 6.3  
(1.4–28.4) 
1.0 
 (0.2–5.6)
3.5 (1.2–10.1) 2.4  
(0.4–15.9)
N/A 
Antithrombin 
deficiency 
0.9  
(0.2–4.5) 
7.6  
(0.3–
196.4) 
3.9 (0.2–97.2) 1.1  
(0.1–18.1)
N/A 
Protein C deficiency 2.3  
(0.2–26.4) 
3.1  
(0.2–38.5)
5.2(0.3–102.2) 5.9  
(0.2–151.6) 
N/A 
Protein S deficiency 3.6 
 (0.4–35.7)
20.1  
(3.7–109.2)
2.8 (0.8–10.6) 2.1  
(0.5–9.3) 
N/A 
Acquired activated 
protein C resistance 
4.0  
(1.7–9.8) 
0.9  
(0.2–3.9)
1.8 (0.7–4.6) 1.3  
(0.4–4.4) 
N/A 
Anticardiolipin 
antibody 
3.4  
(1.3–8.7) 
3.3  
(1.6–6.7)
2.7 (1.7–4.5) 1.4  
(0.4–4.8) 
6.9  
(2.7–17.7) 
Lupus anticoagulant 3.0  
(1.0–8.6) 
2.4  
(0.8–7.0)
1.5 (0.8–2.8) N/A N/A 
Data presented as odds ratios (95-percent confidence intervals). Bolded numbers are statistically 
significant. 
FVL = factor V Leiden, MTHFR = methylenetetrahydrofolate reductase, N/A = data not available. 
Table 5. Obstetrical Complications Associated with Some Inherited and Acquired 
Thrombophilias 
2.3 Treatment 
The treatment of couples with recurrent miscarriage has traditionally been based on 
anecdotal evidence, personal bias, and the results of small uncontrolled studies. There are 
some treatment regimens for APAS that increase live birth rates. The American College of 
Obstetricians and Gynecologists (12) recommends low-dose aspirin—81 mg orally per day, 
along with unfractionated heparin—5000 units subcutaneously, twice daily. This therapy, 
begun when pregnancy is diagnosed, is continued until delivery. Although this treatment 
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may improve overall pregnancy success, these women remain at high risk for preterm labor, 
prematurely ruptured membranes, fetal-growth restriction, preeclampsia, and placental 
abruption (4). The Cochrane review of immune therapy for RPL also addressed IVIg therapy 
and reported that its use did not alter pregnancy outcomes in patients with otherwise 
unexplained RPL (29). Although both vaginal and intramuscular progesterone therapy are 
associated with few minor side effects, their efficacy in the treatment of either unexplained 
RPL or RPL associated with TH cell dysregulation has never been investigated 
appropriately. The efficacy and side effects of prednisone plus low-dose aspirin was 
examined in a recent, large, randomized, placebo-controlled trial treating patients with 
autoantibodies and RPLs. Pregnancy outcomes for treated and control patients were similar; 
however, the incidence of maternal diabetes and hypertension and the risk of premature 
delivery were all increased among those treated with prednisone and aspirin(30). Treatment 
for thrombophilias remains contraversial, but may include heparin and aspirin. Recently, 
Cochrane Database review concluded that women with recurrent miscarriage and 
thrombophilia do not benefit from aspirin or heparin therapy (31) . Vitamins B6, B12, and 
folate are important in homocysteine metabolism and hyperhomocysteinemia is linked to 
RPL. Women with RPL and isolated fasting hyperhomocysteinemia should be offered 
supplemental folic acid (0.4–1.0 mg/day), vitamin B6 (6 mg/day), and possibly vitamin B12 
(0.025 mg/day) (32). 
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